Roche's Polatuzumab Vedotin as Combination Therapy & Entrectinib Receives FDA's Priority Review for r/r Diffuse DLBCL & NTRK Fusion-Positive Solid Tumors
Shots:
- The FDA’s PR designation to the combination of Polatuzumab Vedotin + bendamustine (B)+ Rituxan (rituximab- R) vs BR as monothx & Entrectinib are based on GO29365 & STARTRK (1-2- NG) and ALKA-372-001 study for r/r diffuse DLBCL- mROS1 NSCLC & NTRK fusion-positive solid tumors respectively
- GO29365 study results: mOS (12.4 vs 4.7 mos.)- mPFS (7.6 vs 2.0 mos.)- mDOR (10.3 vs 4.1 mos.)- CR (40% vs 18%); STARTRK (1-2- NG) and ALKA-372-001 study results: ORR (57.4% & 77.4%); mDOR (10.4 & 24.6 mos.); IC ORR (54.5% & 55%)
- Polatuzumab vedotin anti-CD79b ADC and has received FDA’s BT and EMA’s PRIME designation for r/r DLBC in 2017 with expected FDA’s approval on 19 Aug-2019. Entrectinib (RXDX-101) is a TRK inhibitor- inhibiting TRK A/B/C and ROS1 proteins with expected FDA approval on 18 Aug-2019
Ref: Roche | Image: Roche
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com